NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB
Post# of 73
(Total Views: 44)
Posted On: 10/24/2025 4:30:27 PM
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress
Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s Virtual Emerging Growth Conference. The Oct. 23, 2025, report highlights the company’s lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the risk of opioid misuse. Market projections estimate annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the category. Following completion of its manufacturing scale-up with Kindeva Drug Delivery, Nutriband expects to begin a human abuse liability study in early 2026 and file a New Drug Application later that year. Noble reaffirmed its Outperform rating and $15 price target, citing Nutriband’s ability to fund R&D through its contract manufacturing division without shareholder dilution.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s Virtual Emerging Growth Conference. The Oct. 23, 2025, report highlights the company’s lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch that releases aversive agents if tampered with, reducing the risk of opioid misuse. Market projections estimate annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the category. Following completion of its manufacturing scale-up with Kindeva Drug Delivery, Nutriband expects to begin a human abuse liability study in early 2026 and file a New Drug Application later that year. Noble reaffirmed its Outperform rating and $15 price target, citing Nutriband’s ability to fund R&D through its contract manufacturing division without shareholder dilution.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)